5-year survival rate 71.26%! "Fudan Tumor" colorectal cancer prevention and treatment of the international leading.

(Health Times reporter Wei Wei in Fudan University affiliated cancer hospital Wang Weihui)
colorectal cancer is called "eat out of the tumor", the incidence of urban population continued to rise, for many years occupied the second of the top ten malignant tumors in Shanghai. Recently, Fudan University Affiliated Oncology Hospital colorectal surgery in the department sponsored the 9th China colorectal oncology junior experts academic conference, the first disclosure of the hospital from 2008 to 2016 nearly 17,000 colorectal cancer patients survival rate data. Data show that "Fudan tumor" colorectal cancer (I-IV period) five-year survival rate of 71.26 percent, reaching the international advanced developed countries level.
according to statistics, the number of patients treated by large intestine surgery at Fudan University's affiliated oncology hospital increased by 17% per year, with more than 50,000 outpatient visits in 2018. In 2018, colorectal surgery completed 2,488 cases of colon cancer root surgery, including 923 laparoscopic surgery.Xu Wei (first from left), director of the department of intestinal surgery at Fudan University's affiliated oncology hospital,
, performed enteroscopy surgery on bowel cancer patients Wang Guangchao/
the decline of bowel cancer in europe and the United States, the key is in prevention and early detection
colorectal cancer is a lifestyle-induced cancer. Professor Cai Sanjun, chief expert of the multidisciplinary comprehensive treatment team for colorectal cancer at Fudan University's affiliated oncology hospital, introduced a phenomenon in which developed countries in Europe and the United States were once "big households" in the incidence of colorectal cancer. In the United States, for example, the incidence of bowel cancer in the United States has been declining at a rate of 3% for 20 years, while mortality has declined at a rate of 2% in the previous 10 years, 3% in the last 10 years, and the five-year survival rate has increased from 50% to 66%.
" this sustained decline is no accident, but there is a constant force driving it. Cai Said, this is thanks to a solid level of colorectal cancer prevention work.
years ago, the hospital's colorectal cancer screening process in the Seven Bao community of Yihang achieved remarkable results, which prompted the Shanghai municipal government to list the community stool hidden blood test as a public health service in 2012.
Despite this, Professor Xu Wei, Director of The Department of Colorectal Surgery, found in the study that only 30%-40% of those who were initially sievepositiveed colonoscopy would be further colonoscopy, 60%-70% Even the first screening positive will be because of many concerns and choose not to accept further re-screening, "a good early bowel cancer patients, because of fear of doing intestinal mirror, rigidly dragged to the middle and late stage, the efficacy and prognosis greatly discounted" Professor Xu Wei quite sorry.Genetic testing of peripheral blood
is being used to explore early screening for bowel cancer. The research team of The Oncology Hospital, which won the second prize of the Science and Technology Award of the Shanghai Society of Preventive Medicine in 2018, found that 18 genes can be used as a biomarker for genetic detection and can assist in the early detection and early diagnosis of colorectal cancer. Professor Xu said that in the future, this technology will be combined with the current colorectal cancer community screening technology, is expected to greatly improve the compliance of colorectal cancer screening, further target ingest high-risk groups, improve the risk groups prevention and early detection opportunities. At the
meeting, the early diagnosis and early treatment group of the Colorectal Cancer Committee of the Shanghai Anti-Cancer Association, led by Professor Cai Sanjun and Professor Zheng Ying, Director of the Department of Cancer Prevention, was officially established. It is reported that the future hospital will also open colorectal cancer screening clinic, to further strengthen the health management of high-risk groups of bowel cancer.
colorectal cancer peritoneal metastasis has special treatment
the most difficult to treat a type of bowel cancer peritoneal transfer patients, clinical upper peritoneal transfer is one of the common metastasis of colorectal cancer, such patients have poor prognosis, median survival time is only about 18 months.
for this refractive bowel cancer treatment, the hospital relies on the multidisciplinary comprehensive treatment team platform of colorectal cancer, and adopts the method of surgery and auxiliary treatment, which greatly improves the patient's treatment.
Hospital Deputy Director of Major Surgery, responsible for this technical project of the intestinal surgery Professor Cai Guosheng introduced, colorectal cancer peritoneal metastasis patients are a highly heterogeneous group, research shows that some patients through active high-quality tumor reduction surgery combined celiac heat infusion chemotherapy and systemic chemotherapy can reach more than 30% of the five-year survival rate, breaking the past five years survival rate of almost "zero" treatment "bottleneck."
Hospital colorectal surgery for patients with advanced colorectal cancer with peritoneal metastasis cancer, in the country and Shanghai area, since 2014 actively promote the development of standard high-quality peritoneal tumor reduction surgery and celiac heat perfusion chemotherapy. More than 300 cases have been carried out so far. According to the available follow-up data, "some of these patients, who have lost hope of cure, have regained the opportunity for healing, longer survival and better quality of life through this combination of treatment." Professor Cai said.
, in addition, the hospital's large intestine surgery is also promoting another clinical technology project. In the local progression period of colon cancer patients, the use of auxiliary abdominal hot perfusion chemotherapy to reduce the risk of future peritoneal metastasis, abdominal recurrence, led by the hospital in the national multi-center randomized controlled clinical trial is in progress, the results of the research is expected to provide high-level evidence-based medical evidence and new clinical strategies for the prevention and treatment of colorectal cancer peritoneal transfer.
.